Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09JBP
|
|||
| Former ID |
DAP001266
|
|||
| Drug Name |
Paramethadione
|
|||
| Synonyms |
Isoethadione; Paradione; Parametadiona; Parametadione; Paramethadionum; Parametadione [DCIT]; A 348; Paradione (TN); Parametadiona [INN-Spanish]; Paramethadione (INN); Paramethadione [BAN:INN]; Paramethadione [INN:BAN]; Paramethadionum [INN-Latin]; 3,5-Dimethyl-5-ethyloxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-2,4-oxazolidinedione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Fetal trimethadione syndrome [ICD-11: LD2F.0Y] | Approved | [1], [2], [3] | |
| Seizure disorder [ICD-11: 8A6Z] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Anticonvulsants
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H11NO3
|
|||
| Canonical SMILES |
CCC1(C(=O)N(C(=O)O1)C)C
|
|||
| InChI |
1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3
|
|||
| InChIKey |
VQASKUSHBVDKGU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 115-67-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9615, 7784768, 7847561, 8155802, 10504554, 15170974, 29226988, 46509173, 48416379, 50001336, 51133638, 57324899, 103304186, 104317402, 121362245, 124894455, 126666661, 127339772, 127339773, 127339774, 127339775, 132522418, 134224198, 134338502, 134975033, 135374153, 135904528, 137101269, 139640761, 142319575, 144076322, 160963962, 163263663, 175611118, 176262004, 177513112, 178103835, 179225306, 223440591, 223655529, 226421236, 249907748
|
|||
| ChEBI ID |
CHEBI:7921
|
|||
| SuperDrug ATC ID |
N03AC01
|
|||
| SuperDrug CAS ID |
cas=000115673
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) | Target Info | Blocker | [4] |
| KEGG Pathway | MAPK signaling pathway | |||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Type II diabetes mellitus | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| GABA-B receptor II signaling | ||||
| Nicotine pharmacodynamics pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| Reactome | NCAM1 interactions | |||
| WikiPathways | NCAM signaling for neurite out-growth | |||
| Nicotine Activity on Chromaffin Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7261). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 006800. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.